Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28373495 | 0.84 | CYP2C9 (0.35) | LTA4HCYP2C9 | |
| SCHEMBL20764895 | 0.84 | CYP2C9 (0.36) | SLC1A3SLC1A2SLC1A1CYP2C9TAAR1 | |
| SCHEMBL22311657 | 0.83 | SLC1A3 (0.48) | LTA4HSLC1A3SLC1A2SLC1A1HDAC8 | |
| SCHEMBL17531810 | 0.83 | SLC1A3 (0.48) | LTA4HSLC1A3SLC1A2SLC1A1HDAC8 | |
| SCHEMBL30625935 | 0.80 | SMN1; SMN2 (0.48) | CYP2C9HDAC8 | |
| SCHEMBL20764514 | 0.76 | MLYCD (0.42) | — | |
| SCHEMBL20764516 | 0.76 | MLYCD (0.42) | — | |
| SCHEMBL25209459 | 0.75 | SLC1A3 (0.53) | LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL21690461 | 0.75 | SLC1A3 (0.53) | LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL17477557 | 0.75 | SLC1A3 (0.53) | LTA4HSLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997627-B | Cyst amide derivatives | 亥姆霍兹感染研究中心有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
| CN-110997627-A | Novel cystobacter amide derivatives | 亥姆霍兹感染研究中心有限公司 | 2020-04-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | LTA4H 589/4885SLC1A3 325/4885SLC1A2 449/4885 |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | CTH, CBS, SLC7A11 | LTA4H 754/4885SLC1A3 454/4885SLC1A2 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.